A novel coronavirus vaccine developed by the US pharmaceutical company Johnson & Johnson has been approved for emergency use by the US authorities.
The Food and Drug Administration (FDA) announced on the 27th that it would approve the emergency use of the Johnson & Johnson vaccine for adults over 18 years of age.
The U.S. has thus acquired the third coronavirus vaccine after Pfizer and Modena vaccine.
Unlike Pfizer/Moder or vaccines, which require two doses of Johnson & Johnson’s vaccine, even a single dose is effective. In addition, it can be stored for 3 months in a general refrigerator, so it is easy to handle and is evaluated as a’game changer’ of vaccines.
According to a report previously released by the FDA, the Johnson & Johnson vaccine showed an average of 66% prophylactic effect in phase 3 clinical trials, and the prophylactic effect increased to more than 85% when administered to patients with severe symptoms.
President Joe Biden issued a welcoming statement that day, stating that it is “an encouraging development for our efforts to end the crisis and good news for all Americans.”
President Biden encouraged vaccination, saying, “The more people are vaccinated, the faster they can get over the virus, return to their loved ones, and normalize the economy.”
The U.S. government has purchased 100 million doses of Johnson & Johnson vaccine and plans to distribute approximately 3 to 4 million doses next week.
According to the US Centers for Disease Control and Prevention (CDC), approximately 72.8 million doses of vaccination have been administered by the 27th in the United States.
VOA news
–
–
